MARKET

ESPR

ESPR

Esperion Therape
NASDAQ
1.190
-0.050
-4.03%
Pre Market: 1.210 +0.02 +1.68% 05:19 07/14 EDT
OPEN
1.230
PREV CLOSE
1.240
HIGH
1.240
LOW
1.170
VOLUME
429
TURNOVER
0
52 WEEK HIGH
3.940
52 WEEK LOW
0.6925
MARKET CAP
235.86M
P/E (TTM)
-1.4972
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Esperion (ESPR)
TipRanks · 5d ago
Esperion settles litigation with Accord Healthcare
Seeking Alpha · 6d ago
Esperion Reaches Settlement With Accord Healthcare To Delay U.S. Launch Of Generic NEXLETOL Until At Least April 2040
Benzinga · 6d ago
Esperion Announces It Has Reached Settlement Agreement With Third Abbreviated New Drug Application Filer Not To Market Generic Version Of NEXLETOL Prior to April 19, 2040
Benzinga · 6d ago
Esperion signs settlement with Accord Healthcare over Nexletol generic version
TipRanks · 6d ago
Esperion Therapeutics Inc. Reaches Settlement to Delay Generic NEXLETOL Launch Until 2040
Reuters · 6d ago
ESPERION THERAPEUTICS INC - ACCORD HEALTHCARE AGREES NOT TO MARKET GENERIC NEXLETOL BEFORE APRIL 2040
Reuters · 6d ago
ESPERION REACHES SETTLEMENT AGREEMENT WITH THIRD ANDA FILER NOT TO MARKET GENERIC VERSION OF NEXLETOL® (BEMPEDOIC ACID) PRIOR TO APRIL 19, 2040
Reuters · 6d ago
More
About ESPR
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.

Webull offers Esperion Therapeutics Inc stock information, including NASDAQ: ESPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ESPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ESPR stock methods without spending real money on the virtual paper trading platform.